Analysis of factors affecting time to first treatment
| Parameter . | Learning cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| No. of cases . | HR (95% CI) . | P . | No. of cases . | HR (95% CI) . | P . | |
| Karyotype, abnormal vs normal | 14 vs 51 | 3.33 (2.03-15.66) | .0009 | 34 vs 50 | 7.80 (4.36-25.12) | < .0001 |
| Binet stage, B-C vs A | 8 vs 57 | 4.56 (4.43-89.97) | < .0001 | 19 vs 65 | 3.66 (2.47-26.83) | .0006 |
| CD38 positive vs negative | 29 vs 35 | 3.26 (1.60-7.78) | .0018 | 23 vs 59 | 2.00 (0.91-5.73) | .0786 |
| ZAP-70 positive vs negative | 10 vs 20 | 2.31 (0.81-5.78) | NS | 32 vs 41 | 1.52 (0.70-3.41) | NS |
| IGHV unmutated vs mutated | ND | ND | ND | 21 vs 55 | 2.40 (1.11-7.64) | .0297 |
| Parameter . | Learning cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| No. of cases . | HR (95% CI) . | P . | No. of cases . | HR (95% CI) . | P . | |
| Karyotype, abnormal vs normal | 14 vs 51 | 3.33 (2.03-15.66) | .0009 | 34 vs 50 | 7.80 (4.36-25.12) | < .0001 |
| Binet stage, B-C vs A | 8 vs 57 | 4.56 (4.43-89.97) | < .0001 | 19 vs 65 | 3.66 (2.47-26.83) | .0006 |
| CD38 positive vs negative | 29 vs 35 | 3.26 (1.60-7.78) | .0018 | 23 vs 59 | 2.00 (0.91-5.73) | .0786 |
| ZAP-70 positive vs negative | 10 vs 20 | 2.31 (0.81-5.78) | NS | 32 vs 41 | 1.52 (0.70-3.41) | NS |
| IGHV unmutated vs mutated | ND | ND | ND | 21 vs 55 | 2.40 (1.11-7.64) | .0297 |
NS indicates not significant; and ND, not done.